Arcus and Summit Partner on Kidney Cancer Combination Therapy Trial
Event summary
- Arcus Biosciences and Summit Therapeutics will collaborate on a clinical trial to evaluate the combination of casdatifan (HIF-2α inhibitor) and ivonescimab (PD-1/VEGF bispecific antibody) in clear cell renal cell carcinoma (ccRCC).
- The study will be added as a new cohort to Arcus’s ARC-20 platform trial, with initial data expected by mid-2027.
- Summit will supply ivonescimab, while Arcus will conduct and sponsor the combination study; both companies will share study costs and retain commercial rights to their respective molecules.
The big picture
This collaboration aligns with a broader industry trend of exploring novel combination therapies in oncology, particularly for hard-to-treat cancers like ccRCC. The partnership leverages Arcus’s expertise in HIF-2α inhibition and Summit’s bispecific antibody technology to address unmet needs in kidney cancer treatment.
What we're watching
- Clinical Efficacy
- Whether the combination of casdatifan and ivonescimab demonstrates superior efficacy in ccRCC compared to existing treatments.
- Regulatory Pathway
- The pace at which Arcus and Summit can advance this combination through clinical trials and potential regulatory approvals.
- Commercial Strategy
- How each company plans to leverage the trial results to strengthen their respective oncology portfolios in kidney cancer.